Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lineage Cell TherapeuticsLCTX -0.88%74 3-Year EBITDA Growth Rate is 10.40% as of Jun. 2026, which is 3367% above its 10-year median of 0.30. GuruFocus rates LCTX with a GF Score™ of 74/100 and a GF Value™ of $1.17 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,129 Biotechnology companies, Lineage Cell Therapeutics ranks worse than 55.62% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 10.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 17.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Lineage Cell Therapeutics was 48.50% per year. The lowest was -61.20% per year. And the median was 0.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Lineage Cell Therapeutics 3-Year EBITDA Growth Rate Related Terms
LCTX vs NAGE, IFRX, VRXA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Lineage Cell Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 10.40% mean?
Lineage Cell Therapeutics (LCTX) has a 3-Year EBITDA Growth Rate of 10.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lineage Cell Therapeutics and its competitors. This is 3367% above median its historical median of 0.30. According to the industry distribution chart, Lineage Cell Therapeutics ranks #628 out of 1129 companies in the Biotechnology industry, placing it in the top 55.6%.
Is Lineage Cell Therapeutics' 3-Year EBITDA Growth Rate too high?
Lineage Cell Therapeutics' current 3-Year EBITDA Growth Rate of 10.40% is 3367% above median its 10-year median of 0.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Lineage Cell Therapeutics' value of 10.40% is 30.2% below this industry median. Based on the distribution chart, Lineage Cell Therapeutics ranks #628 out of 1129 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lineage Cell Therapeutics has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' 3-Year EBITDA Growth Rate compare to NAGE and IFRX?
According to the Biotechnology industry distribution chart, Lineage Cell Therapeutics ranks #628 out of 1129 companies for 3-Year EBITDA Growth Rate. This places Lineage Cell Therapeutics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Lineage Cell Therapeutics' value of 10.40% is 30.2% below this benchmark. While the company's 10-year median is 0.30 vs. the industry median of 14.90, Lineage Cell Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lineage Cell Therapeutics's current 3-Year EBITDA Growth Rate of 10.40% is 30.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lineage Cell Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lineage Cell Therapeutics's current 3-Year EBITDA Growth Rate is 10.40%, which is 3367% above median its own 10-year median of 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.17, compared to a current price of $1.12 — trading 4.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 10.40%, which is 3367% above median its 10-year median of 0.30 and 30.2% below the Biotechnology industry median of 14.90. Lineage Cell Therapeutics' overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current 3-Year EBITDA Growth Rate is 10.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?
Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued.
The current stock price of $1.12 is trading 4.3% below its estimated GF Value™ of $1.17.
GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.
Key valuation signals for LCTX:
3-Year EBITDA Growth Rate: 10.40% (3367% above median its 10-year median of 0.30)
GF Value™: $1.17 vs. price of $1.12 (4.3% below fair value)
Industry Position: 30.2% below the Biotechnology median (#628 of 1129)
No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
74GF Score
Get the complete analysis for LCTX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCTX has been successfully added to your 
